Zuccarino Sara, Monacelli Fiammetta, Antognoli Rachele, Nencioni Alessio, Monzani Fabio, Ferrè Francesca, Seghieri Chiara, Antonelli Incalzi Raffaele
Management and Health Laboratory, Institute of Management-Department Embeds, Sant'Anna School of Advanced Studies, 56127 Pisa, Italy.
Department of Internal Medicine and Medical Specialties (DIMI), Università di Genova, 16132 Genoa, Italy.
Cancers (Basel). 2022 Jun 30;14(13):3235. doi: 10.3390/cancers14133235.
The Comprehensive Geriatric Assessment (CGA) and the corresponding geriatric interventions are beneficial for community-dwelling older persons in terms of reduced mortality, disability, institutionalisation and healthcare utilisation. However, the value of CGA in the management of older cancer patients both in terms of clinical outcomes and in cost-effectiveness remains to be fully established, and CGA is still far from being routinely implemented in geriatric oncology. This narrative review aims to analyse the available evidence on the cost-effectiveness of CGA adopted in geriatric oncology, identify the relevant parameters used in the literature and provide recommendations for future research. The review was conducted using the PubMed and Cochrane databases, covering published studies without selection by the publication year. The extracted data were categorised according to the study design, participants and measures of cost-effectiveness, and the results are summarised to state the levels of evidence. The review conforms to the SANRA guidelines for quality assessment. Twenty-nine studies out of the thirty-seven assessed for eligibility met the inclusion criteria. Although there is a large heterogeneity, the overall evidence is consistent with the measurable benefits of CGA in terms of reducing the in-hospital length of stay and treatment toxicity, leaning toward a positive cost-effectiveness of the interventions and supporting CGA implementation in geriatric oncology clinical practice. More research employing full economic evaluations is needed to confirm this evidence and should focus on CGA implications both from patient-centred and healthcare system perspectives.
综合老年评估(CGA)及相应的老年干预措施,对于社区居住的老年人而言,在降低死亡率、残疾率、机构化率以及医疗保健利用率方面是有益的。然而,CGA在老年癌症患者管理中的临床疗效和成本效益方面的价值仍有待充分确立,而且CGA在老年肿瘤学中仍远未得到常规实施。本叙述性综述旨在分析老年肿瘤学中采用CGA的成本效益的现有证据,确定文献中使用的相关参数,并为未来研究提供建议。该综述使用PubMed和Cochrane数据库进行,涵盖已发表的研究,不按发表年份进行筛选。提取的数据根据研究设计、参与者和成本效益衡量指标进行分类,并总结结果以说明证据水平。该综述符合质量评估的SANRA指南。在评估 eligibility 的三十七项研究中,有二十九项符合纳入标准。尽管存在很大的异质性,但总体证据与CGA在缩短住院时间和降低治疗毒性方面的可衡量益处一致,倾向于干预措施具有积极的成本效益,并支持在老年肿瘤学临床实践中实施CGA。需要更多采用全面经济评估的研究来证实这一证据,并且应从以患者为中心和医疗保健系统的角度关注CGA的影响。